Open AccessOptimizing Treatment of Chronic Lymphocytic Leukemia
Author(s) -
Sandra Kurtin
Publication year - 2021
Publication title -
journal of the advanced practitioner in oncology
Language(s) - English
Resource type - Journals
eISSN - 2150-0886
pISSN - 2150-0878
DOI - 10.6004/jadpro.2021.12.3.23
Subject(s) - medicine , chronic lymphocytic leukemia , refractory (planetary science) , first line treatment , adverse effect , personalization , leukemia , oncology , intensive care medicine , chemotherapy , world wide web , physics , astrobiology , computer science
During JADPRO Live Virtual 2020, Sandra Kurtin, PhD, ANP-C, AOCN®, described personalization of the treatment of chronic lymphocytic leukemia (CLL) using molecular attributes of the disease, as well as patient characteristics. Dr. Kurtin discussed front-line treatment in previously untreated patients, treatment for relapsed or refractory CLL, and how to prevent, mitigate, and manage adverse events in order to optimize treatment.